No headlines found.
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
Business Wire (Tue, 25-Aug 8:00 AM ET)
Globe Newswire (Mon, 27-Jul 8:00 AM ET)
AtriCure to Participate at Upcoming Investor Conferences
Business Wire (Mon, 27-Jul 8:00 AM ET)
AtriCure Reports Second Quarter 2026 Financial Results
Business Wire (Thu, 23-Jul 4:01 PM ET)
AtriCure to Announce Second Quarter 2026 Financial Results
Business Wire (Thu, 2-Jul 8:00 AM ET)
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
Business Wire (Wed, 27-May 8:00 AM ET)
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Atricure trades on the NASDAQ stock market under the symbol ATRC.
As of August 26, 2026, ATRC stock price declined to $48.17 with 825,868 million shares trading.
ATRC has a beta of 0.36, meaning it tends to be less sensitive to market movements. ATRC has a correlation of 0.01 to the broad based SPY ETF.
ATRC has a market cap of $2.45 billion. This is considered a Mid Cap stock.
Last quarter Atricure reported $154 million in Revenue and $.18 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.15.
In the last 3 years, ATRC traded as high as $49.88 and as low as $18.94.
The top ETF exchange traded funds that ATRC belongs to (by Net Assets): IWM, VTI, VB, FESM, VBK.
ATRC has outperformed the market in the last year with a price return of +27.3% while the SPY ETF gained +20.4%. ATRC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +70.3% and +12.2%, respectively, while the SPY returned +3.0% and -0.6%, respectively.
ATRC support price is $47.31 and resistance is $50.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATRC shares will trade within this expected range on the day.